Oncode Investigator Jan Hoeijmakers is quoted in Volkskrant in an article about the genetic advantages of a redfish species that can live up to 200 years. In Hoeijmakers' view, these findings add to the growing pile of evidence that DNA repair plays an important role in slowing down aging.

Oncode Investigator Alexander van den Oudenaarden is interviewed by MedNet about the new PERSIST-SEQ consortium. This consortium will investigate why cancer often comes back after treatment and then becomes resistant to the treatment that was successful in the first place. As project lead of the PERSIST-SEQ consortium, van den Oudenaarden describes the role of Oncode Institute in this project. 

An extensive interview with Oncode Investigator Sjoerd van der Burg on the start of a new clinical trial of a vaccine against non-small cell lung cancer was featured in the newspaper AD. The vaccine teaches the immune system of lung cancer patients to recognize and clear tumour cells. The vaccine was developed by van der Burg and colleagues at the LUMC and Erasmus MC.

Oncode Investigator Emile Voest talks about the benefits of whole genome sequencing. He describes how this can help determine standard and experimental treatments for cancer patients.

Oncode Investigator Hans Clevers appeared on the Dutch TV Programme Op1 to talk about his switch to the Swiss biopharmaceutical company Roche.

Zorgkrant writes about Oncode Researcher Julie Nonnekens receiving the Starting Grant from the European Research Council (ERC). The grant will be used for her research on targeted radionuclide therapy for cancer, a promising treatment for metastatic cancer.

Dutchnews.nl writes about Oncode Institute and ArgoBio launching Laigo Bio: a targeted biotech for protein degradation with programmes in oncology and neurological disorders. Oncode Investigator Madelon Maurice is the Principal Investigator for this biotech.